BACKGROUND: In recent years, the incidence of hematological tumors has increased. The tumor microenvironment (TME) is the local biological environment in the process of tumor occurrence and development and is closely related to hematological malignancies, including lymphoma and leukemia. This study aims to conduct a bibliometric analysis of the research on the hematological TME, reflect the general situation of the research in this field, and remind the focus of future research.
METHODS: Search the Science Citation Index Expanded (SCI-E) database on the Web of Science Core Collection (WOSCC). Use subject terms to search tumor microenvironment; the limited search subject is Hematology, and the time range is from 1990 to July 18, 2021. Use CiteSpace software to analyze the number of annual papers published, the number of citations, the distribution of disciplines, the distribution of countries/institutions, the distribution of authors, the distribution of journals, and the frequency of use of keywords and its trend of change.
RESULTS: There were 1,992 related research articles cited 77,213 times. The top 5 countries with the number of published papers in this field are: the United States, Italy, China, Germany, and the United Kingdom; the top 5 centrally ranked countries are the United States, Italy, Spain, France, and Japan. Literature and cooperation are mainly from the United States. The top three researchers with several published papers are Anderson KC, Ansell SM, and Gascoyne RD. Their centrality scores are all low, with only 5 researchers reaching above 0.01, and there is less collaboration between the authors. High-quality papers are from , , , and . Keyword analysis shows that immunotherapy is the current focus of research in this field.
CONCLUSIONS: The research on the microenvironment of hematological malignancies is rapidly developing. At present, the main research focus is on targeted immunotherapy.
Cell. 2019 Mar 7;176(6):1248-1264
[PMID:
30849371]
Leuk Lymphoma. 1999 Jun;34(1-2):35-43
[PMID:
10350330]
Br J Biomed Sci. 2013;70(3):110-20
[PMID:
24273897]
N Engl J Med. 2020 Oct 22;383(17):1613-1623
[PMID:
33085860]
Oral Oncol. 2019 Dec;99:104324
[PMID:
31178339]
Eur J Pharmacol. 2019 Nov 5;862:172641
[PMID:
31493406]
JAMA Netw Open. 2019 Dec 2;2(12):e1918007
[PMID:
31860106]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[PMID:
15761078]
Am Soc Clin Oncol Educ Book. 2020 May;40:302-313
[PMID:
32421455]
Adv Clin Exp Med. 2019 Feb;28(2):271-276
[PMID:
30141284]
Cancer J. 2019 Nov/Dec;25(6):378-385
[PMID:
31764118]
CA Cancer J Clin. 2018 Nov;68(6):394-424
[PMID:
30207593]
Nature. 2000 Sep 14;407(6801):249-57
[PMID:
11001068]
Science. 2015 Apr 3;348(6230):56-61
[PMID:
25838373]
Cancer Res. 2019 Sep 15;79(18):4557-4566
[PMID:
31350295]
Surg Pathol Clin. 2016 Mar;9(1):93-100
[PMID:
26940270]
Clin Mol Hepatol. 2018 Jun;24(2):137-143
[PMID:
29961305]
Nature. 2020 Jan;577(7791):474-476
[PMID:
31965091]
Nat Med. 2018 Dec;24(12):1859-1866
[PMID:
30420752]
Immunol Rev. 2015 Jan;263(1):160-72
[PMID:
25510276]
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16569-72
[PMID:
16275915]
Leuk Lymphoma. 1995 Jul;18(3-4):273-9
[PMID:
8535193]
J Exp Med. 1971 Feb 1;133(2):275-88
[PMID:
4332371]
Curr Med Res Opin. 2020 Sep;36(9):1481-1495
[PMID:
32634056]
J Med Libr Assoc. 2015 Oct;103(4):217-8
[PMID:
26512226]
Blood. 2020 Dec 17;136(25):2851-2863
[PMID:
33113552]
Blood. 2018 May 24;131(21):2283-2296
[PMID:
29666114]
Clin Immunol Immunopathol. 1993 Feb;66(2):91-106
[PMID:
8453790]
Trends Cancer. 2019 Jun;5(6):351-364
[PMID:
31208697]
Science. 1989 Dec 8;246(4935):1306-9
[PMID:
2479986]
Am J Clin Pathol. 2019 Aug 1;152(3):322-346
[PMID:
31367767]
Int J Lab Hematol. 2019 Dec;41(6):717-725
[PMID:
31498973]
Pathobiology. 2020;87(2):55-57
[PMID:
32289800]
Exp Hematol. 1992 Oct;20(9):1077-84
[PMID:
1468541]
